Company Presentation

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a novel class of DARPin therapeutics for medical challenges that other drug modalities cannot readily address. DARPin therapeutics are a new class of custom-built protein drugs based on natural binding proteins that open new dimensions of multi-functionality and multi-target specificity in drug design. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main current focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies.